NEUMORA THERAPEUTICS INCNMRA
ASignal's systematic analysis rates NMRA as Bearish.
Reflects the latest available analysis · analyzed Oct 11, 2026
The case on NMRA
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- RSI indicates oversold conditions (28.05), potentially signaling near-term reversal
- Price trading below Bollinger Lower Band (0.3678), suggesting possible undervaluation
- High cash balance relative to market cap ($116.83M cash vs $89.38M market cap)
- Current ratio of 4.50x indicates strong short-term liquidity
- Negative MACD (-0.198) and MACD histogram below zero indicate bearish momentum
- Price momentum is strongly negative (-0.312), indicating sustained downtrend
- Negative return on equity (-187.11%) and negative return on assets (-73.85%)
- Negative free cash flow (-$99.42M) and negative operating cash flow (-$180.52M)
- High debt-to-equity ratio (1.20x) in a loss-making biotech firm
- Forward P/E of -0.71x and EV/EBITDA of -0.13x indicate unprofitable operations
See the full verdict on NMRA
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes NMRA
Most investors never get a second opinion, let alone several. ASignal runs NMRA past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.